Sanofi Consumer Healthcare India Ltd
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Dec 2023 | Dec 2024 | |
|---|---|---|
| Allegra Market Share (Allergy Category) % ・Standalone data |
|
|
| Avil Market Share (Allergy Category) % ・Standalone data |
||
| City Reach Number of Cities ・Standalone data |
||
| Combiflam Annual Sales Volume Million Tablets ・Standalone data |
||
| Combiflam Market Share (Pain Category) % ・Standalone data |
||
| Combiflam Sales Velocity Strips per minute ・Standalone data |
||
| DePURA Market Share (Vitamin D Category) % ・Standalone data |
||
| Total Employees Number ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Intimation Of Record Date For Payment Of Final Dividend For FY 2025
1d - 3rd AGM on 26 June 2026; book closure 20-26 June; final dividend record date 19 June 2026.
- Intimation Of Book Closure For Payment Of Final Dividend For Fy 2025 1d
-
Intimation Of 3Rd Annual General Meeting Of The Company
1d - 3rd AGM on 26 June 2026; book closure 20–26 June; final dividend record date 19 June.
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
25 May - PwC appointed statutory auditor to fill vacancy; proposed 5-year term from AGM 2026 to 2031.
-
Board Meeting Outcome for Intimation Of Appointment Of Statutory Auditor Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015
25 May - PwC appointed statutory auditor on 25 May 2026, filling vacancy after Kalyaniwalla & Mistry LLP resignation.
Annual reports
Concalls
-
Mar 2026Transcript PPT
Business Overview:[1][2]
SCHIL was formed following its demerger from Sanofi India Limited, to establish a standalone Consumer Healthcare (CHC) business. It operates in the Consumer Healthcare (CHC) sector, providing self-care solutions across various health categories including allergy relief, pain management, and wellness